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Since its creation in 1966, the European Association
for the Study of the Liver (EASL) has established itself
as the leading pan-European association of medical pro-
fessionals dedicated to promoting liver research and care
in Europe. EASL succeeded in becoming a powerful asso-
ciation in the ﬁeld of hepatology with a strong adminis-
trative and ﬁnancial capacity which allows us to sustain
our leading role. EASL’s membership today stands at
over 1500 specialists in liver research and disease care
and our annual meeting is recognised worldwide for its
outstanding quality and relevance. Furthermore, since
the introduction of the Sheila Sherlock Fellowships,
almost 40 young researchers have beneﬁted from support
to their research in a European country diﬀerent from
their country of origin. EASL has also developed bur-
saries to encourage young and promising colleagues
and to facilitate their participation to our scientiﬁc meet-
ings. Finally, the Journal of Hepatology has been for a
long time now, a substantial contribution to the dissemi-
nation of knowledge and expertise across the community
of professionals involved in liver research and care,
acknowledged by a constantly increasing impact factor.
Our achievements are signiﬁcant and yet, there is
always more to be done. Liver diseases are killing too
many people in the European Union (EU), where their
prevalence is now estimated to be 6%, i.e. approximately
29 million people. In spite of their high prevalence, how-
ever, liver diseases are all too often neglected by both
national and EU policy-makers. From a policy perspec-
tive, despite the fact that chronic liver diseases are the ﬁfth0168-8278/$34.00  2008 European Association for the Study of the Liver.
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ority in either EU health or research policy. In addition,
with a signiﬁcant number of diﬀerent diseases (like cardio-
vascular diseases, cancer and diabetes) competing for the
attention of decision-makers and thus inclusion in legisla-
tive measures, liver diseases tend to get lost as a result.
By building on our achievements as a professionals’
organisation, EASL therefore decided to work towards
addressing these shortcomings and to shape the Euro-
pean policy environment. Overall, we aim to win recog-
nition of liver diseases as a major cause of illness and
death aﬀecting too many patients in the EU. To achieve
this aim, a European advocacy and communications
strategy is in the process of being developed. Its objec-
tives are threefold:
 To make liver diseases a priority both in EU public
health policy and research policy.
 To raise EASL’s proﬁle as an association and to
establish its members as points of reference and key
advisors to European policy-makers.
 To increase awareness amongst citizens about the
causes of liver diseases, prevention and screening.
2. Towards building an EASL EU advocacy and
communication strategy
Because we are doctors and professionals, with full-
time jobs (and often multiple functions and responsibil-
ities) and with little experience in policy and advocacy,
we thought it was important, before engaging in advo-
cacy activities in the EU, to better understand the EU
political environment, its workings, its priorities and
current main developments. To this end, in the summerPublished by Elsevier B.V. All rights reserved.
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holder mapping (a benchmarking) which reached the
overarching conclusion that, while liver diseases are
not currently recognised as a priority issue in the EU’s
health policy, there are a number of existing and upcom-
ing EU policy initiatives which are highly relevant to
EASL and to liver diseases and which therefore would
beneﬁt from our expertise being brought to bear.
We also realised that EASL should take a step-by-
step approach vis-a`-vis the EU. Indeed, at ﬁrst, we
should work on those issues which are already on the
EU policy agenda such as research, alcohol and rare dis-
eases. It is only after having achieved conﬁdence in our
advocacy skills, built consensus and strong relationships
with decision-makers and established long-lasting alli-
ances with other organisations, that EASL will be in a
position to deal with the ‘‘bigger picture” and raise
awareness in the EU about liver diseases as a whole.
3. Seeking engagement opportunities for EASL in the EU
TheEASL policy and stakeholdermappingmentioned
above identiﬁed speciﬁc policy areas of particular rele-
vance to EASL in the EU policy arena. These are health
research, speciﬁc diseases like viral hepatitis, non-alco-
holic steatohepatitis or liver cancer, as well as the determi-
nants of liver diseases including nutrition and alcohol.
On research, the Seventh Framework Programme for
Research (FP7) allocates record funds to health between
2007 and 2013. Although liver diseases are not mentioned
speciﬁcally among its priorities, there are opportunities of
including references to liver research in the annual work
programmes and to achieve recognition of liver disease
as a priority in its own right in the next Framework Pro-
gramme. At a meeting with representatives of the Euro-
pean Commission’s Directorate General for Research in
November 2007, EASL was asked to provide input on
projects it wished to see funded under the current research
programme. In January 2008,we have also engaged in dis-
cussionswith theMembers of theEuropeanParliament as
a key step towards securing political support for more
emphasis on liver diseases in the current and future
research priorities of the EU.
On viral hepatitis, EASL’s activities are focused on
two main issues: on the one hand, we wish to increase
research funding for viral hepatitis which, despite being
the most prominent liver disease, remains a low priority
in terms of EU research funding and public health
action. On the other hand, given that viral hepatitis is
on the rise in developing countries, EASL argues for
the recognition of viral hepatitis as a fourth poverty-
related disease (alongside HIV, tuberculosis and
malaria). In this respect, in November 2007, EASL
met with oﬃcials from the Directorate General for the
Development in the European Commission and sought
recognition of hepatitis alongside HIV/AIDS, malariaand tuberculosis. EASL is also in the process of raising
this issue with the French government which will be
leading the organisation of the Euro-Mediterranean
Conference on Health to take place in Egypt in 2008.
EASL is also engaging in activitiesmarkingWorldHep-
atitis Awareness Day (WHAD). On WHAD 2007, EASL
participated in a policy seminar on viral hepatitis in the
European Parliament, and later discussedwith the individ-
ual members of the European Parliament ways to tackle
these diseases atEU level.OnWHAD2008,EASLwill col-
laborate with the European Liver Patients Association
(ELPA) to jointly organise a dedicated seminar in the
European Parliament focused on viral hepatitis in Europe
and calling for more research funding for the development
of the hepatitis C vaccine and the implementation of EU-
wide screening and vaccination programmes.
Liver cancer is another key topic in our policy involve-
ment, mainly due to the status of cancer as the EU’s main
health priority. Given that so many cases of primary liver
cancer are preventable through public health interven-
tions such as promoting viral hepatitis care and manage-
ment, preventing alcohol abuse and encouraging healthy
diets, EASL in collaboration with ELPA has addressed
this issue recently with the current Slovenian Presidency
of the EU, whose main health priority focuses on cancer.
Other areas of EASL’s European policy advocacy
include alcohol-related disorders, healthy diets, rare dis-
eases, organ donation and transplantation. These are
being monitored currently in order to assess the best
way and the most appropriate timing for EASL to con-
tribute to debates on these subjects. In particular, EASL
has recently submitted a response to the public consulta-
tion held by the European Commission in November
2007–February 2008 on European action on rare dis-
eases. In the submission, EASL has recognised that
there is value-added to EU action on rare diseases and
has called on the EU, inter alia, to avoid rigid frame-
works and guidelines and to coordinate public health
activities in close cooperation with European aca-
demic/scientiﬁc associations, in order to maximise the
expertise available to decision-makers.
4. Making the case for the liver
EASL’s involvement in policy issues is an important
opportunity to ‘‘make the case for the liver”. Our dia-
logue with EU decision-makers as well as the develop-
ment of a strong relationship with patients’
associations will complement and maximise EASL’s sci-
entiﬁc expertise and reputation. Our advocacy involve-
ment will ultimately contribute to the wider
recognition of EASL for its scientiﬁc excellence as well
as providing tangible input into EU health policies.
Engaging in EU policy work is a major undertaking.
It will mean translating our scientiﬁc knowledge into
political arguments aimed at encouraging politicians to
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EASL will use its scientiﬁc expertise to advise policy-
makers and to ﬁll the information and perception gaps
that remain with regard to liver diseases. As a commu-
nity of medical professionals, we can all contribute to
EASL’s success in shaping health policies. In this
respect, EASL organised a Seminar on EU policy at
its 43rd Annual Meeting in Milan which provided a
more detailed update on EU policy activities, as well
as opportunities for direct input and discussion.5. Conclusion
Science and policy have the potential to create syner-
gies for the beneﬁt of all. As a leading scientiﬁc associa-
tion, EASL’s role, and our responsibility is to seek
policy recognition for the focus of our activity, so as
to shape an environment conducive to research and
health initiatives on liver diseases. We aim to do this,
and to take scientiﬁc and medical excellence to the next
level.
